Cancer Cell Or Component Thereof Patents (Class 424/277.1)
-
Patent number: 11602554Abstract: The disclosure provides, inter alia, methods and materials involved in treating cancer using a p53 vaccine in combination with a PD-1 pathway inhibitor.Type: GrantFiled: December 8, 2017Date of Patent: March 14, 2023Assignee: CITY OF HOPEInventor: Don J. Diamond
-
Patent number: 11596653Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.Type: GrantFiled: October 19, 2018Date of Patent: March 7, 2023Assignee: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai Li, Huiping Gao, Peng Wang, Hua Jiang, Huamao Wang
-
Patent number: 11590076Abstract: The present invention relates to a cryogel scaffold capable of controlling the degree of degradation and a soft bio-integrated device in which a drug modulating an immunosuppressive action in solid tumor microenvironment is loaded in the scaffold.Type: GrantFiled: December 14, 2018Date of Patent: February 28, 2023Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: Yong Taik Lim, Chanyoung Song, Phuengkham Hathaichanok, Long Ren
-
Patent number: 11564980Abstract: Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ a combination vaccination together with immune modulatory treatment and biasing of an immune response towards a Th1 profile.Type: GrantFiled: October 17, 2019Date of Patent: January 31, 2023Assignee: NantCell, Inc.Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong
-
Patent number: 11559552Abstract: The invention relates to the isolation or extraction of exosomes.Type: GrantFiled: June 3, 2022Date of Patent: January 24, 2023Assignee: Exopharm LimitedInventors: Chacko Joseph, Jim Palmer, Ian Dixon, Gregor Lichtfuss
-
Patent number: 11529153Abstract: An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.Type: GrantFiled: April 29, 2021Date of Patent: December 20, 2022Assignees: UNIVERSITY OF WASHINGTON, Seattle Children's HospitalInventors: James Chen, Tanner Clark, Thomas Lendvay
-
Patent number: 11504419Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.Type: GrantFiled: October 26, 2018Date of Patent: November 22, 2022Assignees: BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
-
Patent number: 11485790Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.Type: GrantFiled: April 7, 2015Date of Patent: November 1, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Taro Miyazaki, Kenji Taniguchi, Naoka Hironiwa
-
Patent number: 11464838Abstract: The present invention provides cancer stem cell vaccines useful for treating or preventing a variety of tumors, as well as related methods of producing cancer stem cells and antigens thereof and producing vaccine adjuvants with enhanced activity for use with the stem cell vaccines.Type: GrantFiled: April 1, 2016Date of Patent: October 11, 2022Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Lyndah Chow, Steven W. Dow, Amanda M. Guth, Daniel P. Regan
-
Patent number: 11447561Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.Type: GrantFiled: December 18, 2019Date of Patent: September 20, 2022Assignee: Intervet, Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Patent number: 11401506Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: GrantFiled: December 20, 2018Date of Patent: August 2, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board nf Regents The Inivercitvof Texas CvctomInventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
-
Patent number: 11361841Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.Type: GrantFiled: February 10, 2017Date of Patent: June 14, 2022Assignee: Nantomics LLCInventors: Andrew Nguyen, John Zachary Sanborn, Stephen Charles Benz, Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong, Charles Joseph Vaske
-
Patent number: 11352642Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: January 7, 2016Date of Patent: June 7, 2022Assignee: Etubics CorporationInventors: Frank R. Jones, Elizabeth Gabitzsch, Yvette Latchman, Adrian Rice
-
Patent number: 11351252Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.Type: GrantFiled: June 26, 2019Date of Patent: June 7, 2022Assignee: SNIPR Technologies LimitedInventor: Jasper Clube
-
Patent number: 11338029Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.Type: GrantFiled: December 13, 2018Date of Patent: May 24, 2022Assignee: Inovio Pharmaceuticals, Inc.Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
-
Patent number: 11229689Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: GrantFiled: March 17, 2021Date of Patent: January 25, 2022Assignee: SYZ Cell Therapy Co.Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Longqing Tang, Ran Tao
-
Patent number: 11219675Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: GrantFiled: December 8, 2020Date of Patent: January 11, 2022Assignee: SYZ Cell Therapy Co.Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Ran Tao, Longqing Tang
-
Patent number: 11192948Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.Type: GrantFiled: September 29, 2016Date of Patent: December 7, 2021Assignee: MedImmune LimitedInventors: Elaine M. Hurt, Ralph Minter, Steven Rust, Alan Sandercock, Sotirios Karathanasis
-
Patent number: 11160853Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.Type: GrantFiled: March 29, 2019Date of Patent: November 2, 2021Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATONInventors: Mary L. Disis, Denise Cecil, Meredith Slota
-
Patent number: 11156617Abstract: The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.Type: GrantFiled: February 9, 2016Date of Patent: October 26, 2021Assignees: BioNTech RNA Pharmaceuticals GbmH, TRON-Translationale Onkologie an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Martin Löwer, Arbel D. Tadmor, Sebastian Boegel, Barbara Schrörs, Mathias Vormehr, Sebastian Kreiter
-
Patent number: 11142769Abstract: The present invention provides a single-stranded nucleic acid molecule having a delivery function and capable of inhibiting expression of a target gene. The single-stranded nucleic acid molecule of the present invention is a single-stranded nucleic acid molecule composed of a region (Xc), a linker region (Lx) and a region (X), wherein said region (Xc) is complementary to said region (X), at least one of said region (X) and said region (Xc) contains an expression inhibitory sequence that inhibits expression of the target gene, and a bio-related substance having a delivery function is bonded to at least one selected from the group consisting of the 5?-terminus, the 3?-terminus, and said linker region (Lx).Type: GrantFiled: March 26, 2016Date of Patent: October 12, 2021Assignee: BONAC CORPORATIONInventors: Eriko Aoki, Shiori Kato, Tadaaki Ohgi
-
Patent number: 11141432Abstract: Provided herein are materials and methods for treating a cancer and/or an infection in a mammal. One or more mitochondrial protein uncoupling protein 2 (UCP2) inhibitors can be administered to a mammal to enhance an immune response produced against an antigen (e.g., a tumor associated antigen or a pathogen associated antigen) present within the mammal.Type: GrantFiled: March 2, 2017Date of Patent: October 12, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Protul Shrikant, Leena Chaudhuri
-
Patent number: 11142547Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.Type: GrantFiled: March 7, 2019Date of Patent: October 12, 2021Assignee: Genoimmune Therapeutics Co., Ltd.Inventors: Shuntao Luo, Xiumei Lin, Ting An, Bo Li, Yong Hou
-
Patent number: 11112410Abstract: The invention relates to methods of detection, capture, isolation and targeting of cancer cells for example circulating tumor cells (CTCs) using carbohydrate recognition domain of a lectin. The invention relates to methods of diagnosis, prognosis and treatment of cancer.Type: GrantFiled: April 10, 2017Date of Patent: September 7, 2021Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Joo-Hun Kang, Donald E. Ingber, Michael Super, Alexander L. Watters, Harry Scott Driscoll
-
Patent number: 11096975Abstract: The use of at least one flavonoid of natural or synthetic origin in association with cyclophosphamide and/or methotrexate to increase the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumors is described, in particular in case of resistance to the chemotherapeutic agents currently in use. At least one flavonoid herein described is selected from the group comprising or, alternatively, consisting of rutin, oxerutin, diosmin, troxerutin and hesperidin.Type: GrantFiled: March 4, 2016Date of Patent: August 24, 2021Assignee: PROBIOTICAL S.P.A.Inventor: Giovanni Mogna
-
Patent number: 11096995Abstract: The invention describes a method for preparing a composition comprising tumour cell stress proteins, said method comprising the following steps: providing tumour cells in a culture medium; subjecting the tumour cells under i) to a stress with the result that these cells produce stress proteins in response to the stress; obtaining or recovering stressed tumour cells and/or stress proteins; treating the stressed tumour cells and/or the stress proteins obtained with a molecule or a process capable of rendering the stress proteins immunogenic, preferably a hapten or haptenization. The invention also describes a pharmaceutical composition comprising tumour cell stress proteins and/or tumour cells comprising stress proteins, these stress proteins being rendered immunogenic, and are in particular haptenized, and a pharmaceutically acceptable excipient.Type: GrantFiled: August 20, 2018Date of Patent: August 24, 2021Assignee: BRENUS PHARMAInventors: Benoît René Eugène Pinteur, Gilles Guy Devillers
-
Patent number: 11069054Abstract: A method of treating a malignancy in a human subject by analyzing pseudo-projection images of cells obtained from a sputum specimen obtained from a subject employs a biological specimen classifier that identifies cells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cells are further classified as dysplastic or cancerous. If the cells are classified as dysplastic, then an immunomodulating agent is administered to the subject over a predetermined time period designed to achieve a therapeutic dosage.Type: GrantFiled: January 11, 2017Date of Patent: July 20, 2021Assignee: VisionGate, Inc.Inventors: Alan C. Nelson, Michael G. Meyer, Daniel J. Sussman
-
Patent number: 11054389Abstract: MCE assays and reagents to assess purity and to identify impurities in protein drug product samples are provided. Methods for analyzing analytes in a protein drug sample are provided.Type: GrantFiled: March 15, 2019Date of Patent: July 6, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Timothy Riehlman, Gabriel Carreau, Jeffrey Schneiderheinze, Nicole M. Nall
-
Patent number: 11040094Abstract: The present invention is directed to methods of lymphotherapy to treat cancer, infection and autoimmune disease.Type: GrantFiled: July 1, 2016Date of Patent: June 22, 2021Inventor: Colleen M. O'Connor
-
Patent number: 11028139Abstract: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.Type: GrantFiled: May 31, 2018Date of Patent: June 8, 2021Assignee: NEXEL CO., LTD.Inventors: Choong Seong Han, Dong Hun Woo, Gun Sik Cho, Jeong Seong Kim, Geun Ho An, Hye Ryeon Jeon
-
Patent number: 11017529Abstract: A method is for determining at least one first characteristic value of blood in a patient. In an embodiment, the method includes acquiring, via a computed tomography device, computed tomography data of the patient for at least two energy levels of radiation using multi-energy computed tomography; defining a region of interest including blood, in at least one image data set reconstructed from the computed tomography data acquired; determining, at least in the region of interest defined, attenuation coefficients for each energy level of the at least two energy levels; performing material decomposition into at least two materials, one material of the two materials being iron, using the attenuation coefficients determined, yielding at least a fraction of iron in the region of interest defined; and determining the at least one first characteristic value, at least one of as and from the fraction of iron yielded.Type: GrantFiled: April 17, 2019Date of Patent: May 25, 2021Assignee: SIEMENS HEALTHCARE GMBHInventors: Jing Yan, Thomas Flohr, Bernhard Schmidt
-
Patent number: 10995140Abstract: A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express GM-CSF and CD40 ligand. In some embodiments, the checkpoint inhibitor comprises an anti-PD-1 antibody (e.g., BMS 936558), anti-PD-L1 antibody (e.g., cloneM1H1), anti-CTLA-4 antibody (e.g., Ipilimumab, BMS), or any combination thereof.Type: GrantFiled: June 3, 2016Date of Patent: May 4, 2021Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor: Scott Antonia
-
Patent number: 10987419Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.Type: GrantFiled: December 6, 2017Date of Patent: April 27, 2021Assignee: Emory UniversityInventor: Periasamy Selvaraj
-
Patent number: 10946078Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.Type: GrantFiled: April 26, 2017Date of Patent: March 16, 2021Assignee: BENCHMARK ANIMAL HEALTH LTD.Inventor: Kaspars Tars
-
Patent number: 10934363Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.Type: GrantFiled: August 10, 2016Date of Patent: March 2, 2021Assignee: Legend Biotech USA Inc.Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
-
Patent number: 10919933Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 16, 2020Date of Patent: February 16, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
-
Patent number: 10906938Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 16, 2020Date of Patent: February 2, 2021Assignee: Immatics Biotechnologies GmbHInventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
-
Patent number: 10899794Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 16, 2020Date of Patent: January 26, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
-
Patent number: 10899784Abstract: Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biosynthetic pathway and methods of treating a disease using the inhibitors.Type: GrantFiled: August 14, 2015Date of Patent: January 26, 2021Assignee: The Johns Hopkins UniversityInventors: Kevin J. Yarema, Christopher T. Saeui, Alfredo Quinones-Hinojosa, Sagar Ramesh Shah
-
Patent number: 10899806Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 17, 2020Date of Patent: January 26, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10889617Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 29, 2019Date of Patent: January 12, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
-
Patent number: 10851422Abstract: The present disclosure provides method for determining an immune response score (irScore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irScore=X(low, medium, or high), wherein X is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.Type: GrantFiled: September 15, 2017Date of Patent: December 1, 2020Assignee: American Molecular Laboratories Inc.Inventors: Sarah S. Bacus, Christopher A. Hamm
-
Patent number: 10808230Abstract: In some aspects, isolated transgenic cells (e.g., transgenic T cells) are provided that comprise or express a transgene and DHFRFS and/or TYMSSS. Methods for selecting transgenic cells are also provided.Type: GrantFiled: February 24, 2016Date of Patent: October 20, 2020Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: David Rushworth, Laurence J. N. Cooper
-
Patent number: 10792349Abstract: Compositions for the treatment of cancer include an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cell vaccine and an anti-galectin-3 antibody. Increased titers of anti-galectin-3 antibodies were correlated with clinical outcome.Type: GrantFiled: May 9, 2016Date of Patent: October 6, 2020Assignee: The Johns Hopkins UniversityInventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
-
Patent number: 10774343Abstract: Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.Type: GrantFiled: April 24, 2015Date of Patent: September 15, 2020Assignee: bluebird bio, Inc.Inventors: Richard Morgan, Kevin Friedman, Byoung Ryu
-
Patent number: 10724027Abstract: The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.Type: GrantFiled: September 17, 2013Date of Patent: July 28, 2020Assignee: MINERVA BIOTECHNOLOGIES CORPORATIONInventor: Cynthia Bamdad
-
Patent number: 10695409Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.Type: GrantFiled: May 31, 2017Date of Patent: June 30, 2020Assignees: INVECTYS, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCONInventors: Pierre Langlade Demoyen, Olivier Adotevi, Magalie Dosset
-
Patent number: 10695408Abstract: Disclosed is an antitumor vaccine including testicular and fetal tissue-derived components. Cell preparations are prepared from normal tissues harvested directly from animals. Such vaccines may be used in the treatment and prevention of different cancers. For example, a vaccine consisting of glutaraldehyde-treated cells prepared from sheep testis and fetal lung has been found to be effective in inducing antitumor cell-mediated responses, as well as in prolonging the survival of mice with lung cancer.Type: GrantFiled: April 15, 2015Date of Patent: June 30, 2020Assignee: UAB “Innovita Research”Inventors: Victor I. Seledtsov, Galina V. Seledtsova, Adas Darinskas
-
Patent number: 10617749Abstract: This disclosure provides compositions of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy. The compositions and methods can involve regulation of fatty acid oxidation.Type: GrantFiled: February 24, 2017Date of Patent: April 14, 2020Assignee: Duke UniversityInventors: Brent Hanks, Fei Zhao
-
Patent number: 10577585Abstract: Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to an activator for activating expansion of the cells. The cells may in embodiments include T cells, and the activator may be in different forms, including, for example, antigen presenting cells or beads functionalized with antibodies.Type: GrantFiled: May 12, 2016Date of Patent: March 3, 2020Assignee: Terumo BCT, Inc.Inventors: Kim Thien Duy Nguyen, Thomas Patrick Startz, Alexander L. Howard